Holen Sie sich die Stockscreener-App
6.12
3.01%
-0.19
Handel nachbörslich:
6.08
-0.04
-0.65%
Schlusskurs vom Vortag:
$6.31
Offen:
$6.31
24-Stunden-Volumen:
2.50M
Relative Volume:
1.08
Marktkapitalisierung:
$792.14M
Einnahmen:
$8.40M
Nettoeinkommen (Verlust:
$-237.42M
KGV:
-3.1853
EPS:
-1.9213
Netto-Cashflow:
$-377.03M
1W Leistung:
-14.53%
1M Leistung:
-22.92%
6M Leistung:
-75.52%
1J Leistung:
+32.75%
1-Tages-Spanne:
$6.01
$6.31
1-Wochen-Bereich:
$6.01
$7.31
52-Wochen-Spanne:
$4.37
$31.35
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
6.12 | 792.14M | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2026-09-02 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-05-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (Nasdaq:ALMS)Stock Analysis - simplywall.st
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Why is Alumis stock rallying today? By Investing.com - Investing.com Canada
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Wednesday’s top insider buys and sells: NVIDIA leads activity - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Australia
Alumis at Cantor conference: psoriasis strength, lupus setback - investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Canada
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com India
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com UK
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Nigeria
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Australia
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com India
Guggenheim downgrades Alumis stock rating after trial miss - investing.com
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com UK
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Nigeria
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Canada
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com UK
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Nigeria
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com UK
ALMS Stock Slides After IPO Spike As Traders Reset - StocksToTrade
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Sep 08 '26 |
Sale |
10.55 |
96,131 |
1,014,028 |
2,025,493 |
| AKKARAJU SRINIVAS | Director |
Sep 04 '26 |
Buy |
11.17 |
440,140 |
4,917,684 |
4,711,801 |
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Schroer John R. | Chief Financial Officer |
Aug 03 '26 |
Sale |
26.37 |
3,282 |
86,546 |
24,718 |
| SANAMPREET PANGALI | Officer |
Jul 06 '26 |
Proposed Sale |
28.00 |
5,000 |
140,000 |
0 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
5.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):